You are here

solanezumab

Lilly’s Alzheimer’s struggles continue as preclinical asset fails phase III

Lilly’s Alzheimer’s struggles continue as preclinical asset fails phase III

BioSpace

Alzheimer's disease

clinical trials

Flag link:

Lilly and Roche's antibodies fail late-phase Alzheimer's test

Lilly and Roche's antibodies fail late-phase Alzheimer's test

Fierce Biotech

Alzheimer's disease

clinical trials

Flag link:

Preventive Alzheimer's trial data due within weeks, Lilly says

Preventive Alzheimer's trial data due within weeks, Lilly says

BioPharma Dive

Alzheimer's disease

clinical trials

Flag link:

Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer’s

Eli Lilly finally published its disastrous EXPEDITION3 data, a costly lesson in rethinking Alzheimer’s

Endpoints

clinical trials

Alzheimer's disease

Flag link:

Alzheimer’s Drug Pipeline Analysis: Have We Hit Peak Amyloid?

Alzheimer’s Drug Pipeline Analysis: Have We Hit Peak Amyloid?

Xconomy

Alzheimer's disease

Flag link:

Over And Out For Solanezumab, While Biogen Takes The Spotlight

Over And Out For Solanezumab, While Biogen Takes The Spotlight

Seeking Alpha

Alzheimer's disease

Flag link:

Eli Lilly conducts an autopsy of an Alzheimer’s megaflop

Eli Lilly conducts an autopsy of an Alzheimer’s megaflop

Endpoints

Alzheimer's disease

Flag link:

7 of the Most Shocking Biotech Pipeline Blowups of 2016

7 of the Most Shocking Biotech Pipeline Blowups of 2016

Motley Fool

Clovis Oncology

Celldex Therapeutics

Flag link:

Why Eli Lilly Shares Lost 8% in November

Why Eli Lilly Shares Lost 8% in November

Motley Fool

clinical trials

Alzheimer's disease

Flag link:

In Lechleiter’s final days, Eli Lilly flags upcoming job cuts in the wake of a PhIII implosion

In Lechleiter’s final days, Eli Lilly flags upcoming job cuts in the wake of a PhIII implosion

Endpoints

John Lechleiter

Alzheimer's disease

Flag link:

Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies

Lilly's Setback Raises Stakes for Other Alzheimer Drug Companies

TheStreet.com

Alzheimer's disease

Flag link:

Does Lilly's Alzheimer's Fail Hurt Biogen?

Does Lilly's Alzheimer's Fail Hurt Biogen?

Investopedia

Alzheimer's disease

Flag link:

Lilly's sola failure throws Alzheimer's theory into doubt

Lilly's sola failure throws Alzheimer's theory into doubt

BioPharma Dive

Alzheimer's disease

Flag link:

Biogen loses $4 billion in market cap on Eli Lilly Azheimer's news

Biogen loses $4 billion in market cap on Eli Lilly Azheimer's news

Bizjournals.com

Alzheimer's disease

Flag link:

Eli Lilly (LLY) CEO Lechleiter 'Disappointed,' after Alzheimer's Drug Fails

Eli Lilly (LLY) CEO Lechleiter 'Disappointed,' after Alzheimer's Drug Fails

TheStreet.com

Alzheimer's disease

clinical trials

John Lechleiter

Flag link:

[video] Eli Lilly's Alzheimer Drug Fails Final-Stage Trial

[video] Eli Lilly's Alzheimer Drug Fails Final-Stage Trial

Bloomberg

Alzheimer's disease

clinical trials

Flag link:

Solanezumab And The History Of The Future Of Treating Alzheimer's Disease

Solanezumab And The History Of The Future Of Treating Alzheimer's Disease

Forbes

Alzheimer's disease

Flag link:

In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success

In One Expert's View, Eli Lilly's Alzheimer Drug Trial Has A Greater Than 60% Chance Of Success

Yahoo/Benzinga

Alzheimer's disease

Flag link:

Eli Lilly: This is Gonna Be Good

Eli Lilly: This is Gonna Be Good

Barron's

Alzheimer's disease

Flag link:

Pages